Chapel Disease Therapeutics Market Size is valued at USD 144.89 Mn in 2023 and is predicted to reach USD 161.10 Mn by the year 2031 at a 1.41% CAGR during the forecast period for 2024-2031.
Chapel Syndrome is a rare genetic condition affecting the immune system. CHAPLE stands for "CD55 deficiency, hyperactivation, angiopathic thrombosis, and severe protein-losing enteropathy (PLE)." Chaple is characterized by severe protein-losing enteropathy, which can result in hypoproteinemia. Chronic malabsorption is a condition that causes nutrient shortages, including iron, ferritin, and calcium. Patients with significant thrombotic or vascular blockages may also be impacted. CHAPLE syndrome is caused by mutations in the complement regulator gene, which cause a decrease in protein expression.
The Chaple syndrome is primarily inherited as autosomal recessive. This indicates that a child normally inherits one copy of each parent's defective gene, resulting in a homozygous deficiency. Chaple syndrome patients can be diagnosed using a combination of clinical symptoms, genetic testing, and histology. The histopathological examination of intestinal biopsy specimens (or resections) revealed significant lymphangiectasia. This points to a diagnosis of primary intestinal lymphangiectasia. Large-vein thrombosis is also possible in patients. The patient's clinical status determines the treatment plan. Kurolap and his colleagues gave patients off-label eculizumab. This is a humanized monoclonal anti-C5 antibody and complement inhibitor. The treatment was effective for 18 months. The chapel syndrome is a market with an increasing number of patients.
Increased demand for iron supplements, Eculizumab, a blood thinner, and bone marrow transplants for genetically predisposed patients is driving market expansion. Market growth is also affected by pharmaceutical companies' expanded research and development operations to provide additional treatment facilities, as well as an increase in demand for therapies to treat the condition. Research and development, as well as increased research funding, benefit the chapel syndrome market. CHAPLE syndrome is distinguished by complement-mediated autoimmune hemolysis and nocturnal hemoglobinuria. The decay-accelerating element, commonly known as CD55, plays a role in regulating the complement cascade. If CD55 is not present, the complement system targets and destroys blood cells (hemolysis). CD55 deficiency is associated with hyperactivation, angiopathic thrombosis, and CD55 (the CHAPLE Syndrome). Surprisingly, deletion of CD55, a crucial regulator of the complement system, results in a mainly gastrointestinal disease.
The Chaple Disease Therapeutics Market is segmented by type, diagnosis, and distribution channel. Based on type, the market is segmented into Eculizumab, Ravulizumab, and Veopoz. By diagnosis, the market is segmented into Gastrointestinal Symptoms, Edema, Hypoalbuminemia, Hypogammaglobulinemia, and Malnutrition. As per the distribution channel, the market is categorised into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies.
Eculizumab and Ravulizumab are key players in the Chapel Disease market. Both are significant drugs for the treatment of Chapel Syndrome. They are classed as complement inhibitors and work by addressing the disease's underlying cause, a deficit in the complement factor H protein. These drugs have been found to help people with Chapel Syndrome manage their symptoms and improve their quality of life. Veopoz, on the other hand, has no unique association with Chapel Syndrome.
Gastrointestinal symptoms are a popular area of the Chapel Disease market. Chapel Syndrome is defined by a variety of gastrointestinal symptoms, including chronic diarrhea, abdominal pain, and malabsorption. These symptoms substantially influence the quality of life for people with Chapel Syndrome and are frequently addressed in treatment and management measures. Addressing gastrointestinal symptoms is critical to increasing overall well-being and decreasing Chapel Syndrome's influence on everyday living.
North America is predicted to be the most important market for chaple disease therapies throughout the forecast period. The North American area dominates the worldwide chaple disease treatments market due to the existence of numerous leading pharmaceutical companies and high healthcare expenditure. In addition, the Asia Pacific market is predicted to be the fastest-growing for chaple disease therapies, accounting for more than 20% of the market throughout the projection period. The market in Asia Pacific is expanding very fast as a result of positive legislative backing, infrastructure upgrades, and changing customer preferences.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 144.89 Mn |
|
Revenue Forecast In 2031 |
USD 161.10 Mn |
|
Growth Rate CAGR |
CAGR of 1.41% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, Diagnosis, Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Alexion Pharmaceuticals Inc., Akari Therapeutics, Apellis Pharmaceuticals, Amgen Inc., CinnaGen Co., Novartis AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., and Alnylam Pharmaceuticals, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Chaple Disease Therapeutics Market Snapshot
Chapter 4. Global Chaple Disease Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis
5.1. by Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type:
5.2.1. Eculizumab
5.2.2. Ravulizumab
5.2.3. Veopoz
Chapter 6. Market Segmentation 2: by Diagnosis Estimates & Trend Analysis
6.1. by Diagnosis & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Diagnosis:
6.2.1. Gastrointestinal Symptoms
6.2.2. Edema
6.2.3. Hypoalbuminemia
6.2.4. Hypogammaglobulinemia
6.2.5. Malnutrition
Chapter 7. Market Segmentation 3: by Distribution Channel Estimates & Trend Analysis
7.1. by Distribution Channel & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Distribution Channel:
7.2.1. Retail Pharmacies
7.2.2. Hospital Pharmacies
7.2.3. Online Pharmacies
Chapter 8. Chaple Disease Therapeutics Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
8.1.2. North America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
8.1.3. North America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.1.4. North America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.2. Europe
8.2.1. Europe Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
8.2.2. Europe Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
8.2.3. Europe Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.2.4. Europe Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
8.3.2. Asia Pacific Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
8.3.3. Asia-Pacific Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.3.4. Asia Pacific Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.4. Latin America
8.4.1. Latin America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
8.4.2. Latin America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
8.4.3. Latin America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.4.4. Latin America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
8.5.2. Middle East & Africa Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
8.5.3. Middle East & Africa Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.5.4. Middle East & Africa Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Alexion Pharmaceuticals Inc.
9.2.2. Akari Therapeutics, Apellis Pharmaceuticals
9.2.3. Amgen Inc.
9.2.4. CinnaGen Co.
9.2.5. Novartis AG
9.2.6. F. Hoffmann-La Roche Ltd
9.2.7. Regeneron Pharmaceuticals Inc
9.2.8. Alnylam Pharmaceuticals
9.2.9. Inc.
Chaple Disease Therapeutics Market By Type -
Chaple Disease Therapeutics Market By Diagnosis -
Chaple Disease Therapeutics Market By Distribution Channel -
Chaple Disease Therapeutics Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
